BRAF V600E突变儿童胶质瘤反应评估中体积与二维测量及纵向轨迹的比较:太平洋儿童神经肿瘤联盟临床试验
在太平洋儿童神经肿瘤联盟002试验的31例BRAF V600E突变儿童胶质瘤患者(292次随访)中,比较手动体积分割(整体与实性肿瘤)与二维测量,以神经放射科医师使用BT-RADS评估为参照。部分缓解分类的AUC:二维面积0.84、整体体积0.91、实性体积0.92,二维与体积间无显著差异;二维与整体体积模型估计的最佳反应时间无显著相关,25例中8例在部分缓解向稳定疾病转换的时间上相差≥90天。
要点
- 在BRAF V600E突变儿童胶质瘤中,体积与二维测量对BT-RADS部分缓解的分类效能无显著差异。
- 首次检测部分缓解时(中位2个月),实性体积AUC 0.92、整体体积0.91、二维面积0.84。
- 二维与整体体积模型估计的最佳反应时间无显著相关,部分病例轨迹差异可达≥90天。
核心结论
- 尽管体积与二维在BT-RADS部分缓解评估分类上总体无差异,但部分个体中二维与体积轨迹的差异对临床决策和结局的影响需进一步前瞻性研究阐明。
研究设计与样本
- 太平洋儿童神经肿瘤联盟002试验(NCT01748149)中31例BRAF V600E突变儿童胶质瘤患者、292次随访研究;手动体积分割(整体与实性肿瘤)与二维测量比较,两名神经放射科医师使用BT-RADS评估反应,参考标准为BT-RADS部分缓解。
诊断标准与关键数值
- BT-RADS部分缓解分类的ROC分析:首次检测时(中位2个月),二维面积AUC 0.84(95%CI 0.69-0.99),整体体积AUC 0.91(95%CI 0.80-1.00),实性体积AUC 0.92(95%CI 0.82-1.00);二维与实性体积AUC无显著差异(P=.34),二维与整体体积AUC无显著差异(P=.39)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步前瞻性研究以阐明二维与体积轨迹差异对临床决策和结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Response on imaging is widely used to evaluate treatment efficacy in clinical trials of pediatric gliomas. While conventional criteria rely on 2D measurements, volumetric analysis may provide a more comprehensive response assessment. There is sparse research on the role of volumetrics in pediatric gliomas. Our purpose was to compare 2D and volumetric analysis with the assessment of neuroradiologists using the Brain Tumor Reporting and Data System (BT-RADS) in BRAF V600E-mutant pediatric gliomas.
MATERIALS AND METHODS: Manual volumetric segmentations of whole and solid tumors were compared with 2D measurements in 31 participants (292 follow-up studies) in the Pacific Pediatric Neuro-Oncology Consortium 002 trial (NCT01748149). Two neuroradiologists evaluated responses using BT-RADS. Receiver operating characteristic analysis compared classification performance of 2D and volumetrics for partial response. Agreement between volumetric and 2D mathematically modeled longitudinal trajectories for 25 participants was determined using the model-estimated time to best response.
RESULTS: Of 31 participants, 20 had partial responses according to BT-RADS criteria. Receiver operating characteristic curves for the classification of partial responders at the time of first detection (median = 2 months) yielded an area under the curve of 0.84 (95% CI, 0.69-0.99) for 2D area, 0.91 (95% CI, 0.80-1.00) for whole-volume, and 0.92 (95% CI, 0.82-1.00) for solid volume change. There was no significant difference in the area under the curve between 2D and solid (P = .34) or whole volume (P = .39). There was no significant correlation in model-estimated time to best response (ρ = 0.39, P >.05) between 2D and whole-volume trajectories. Eight of the 25 participants had a difference of ≥90 days in transition from partial response to stable disease between their 2D and whole-volume modeled trajectories.
CONCLUSIONS: Although there was no overall difference between volumetrics and 2D in classifying partial response assessment using BT-RADS, further prospective studies will be critical to elucidate how the observed differences in tumor 2D and volumetric trajectories affect clinical decision-making and outcomes in some individuals.
引用
- Ramakrishnan D, Brüningk SC, von Reppert M, et al. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. AJNR Am J Neuroradiol. 2024. PMID: 38453411. doi:10.3174/ajnr.A8189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。